Cargando…

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Objective: High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ≥five years, long-term surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbro, Michel, Colombo, Pierre-Emmanuel, Leaha, Cristina Marinella, Rouanet, Philippe, Carrère, Sébastien, Quenet, François, Gutowski, Marian, Mourregot, Anne, D’Hondt, Véronique, Coupier, Isabelle, Vendrell, Julie, Vilquin, Paul, Pujol, Pascal, Solassol, Jérôme, Mollevi, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465919/
https://www.ncbi.nlm.nih.gov/pubmed/32764409
http://dx.doi.org/10.3390/cancers12082184
_version_ 1783577692675768320
author Fabbro, Michel
Colombo, Pierre-Emmanuel
Leaha, Cristina Marinella
Rouanet, Philippe
Carrère, Sébastien
Quenet, François
Gutowski, Marian
Mourregot, Anne
D’Hondt, Véronique
Coupier, Isabelle
Vendrell, Julie
Vilquin, Paul
Pujol, Pascal
Solassol, Jérôme
Mollevi, Caroline
author_facet Fabbro, Michel
Colombo, Pierre-Emmanuel
Leaha, Cristina Marinella
Rouanet, Philippe
Carrère, Sébastien
Quenet, François
Gutowski, Marian
Mourregot, Anne
D’Hondt, Véronique
Coupier, Isabelle
Vendrell, Julie
Vilquin, Paul
Pujol, Pascal
Solassol, Jérôme
Mollevi, Caroline
author_sort Fabbro, Michel
collection PubMed
description Objective: High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ≥five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis. Methods: Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS. Results: 404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20–89), WHO performance status 0–1 in 86.9% and 2 in 13.1%, and Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1–14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6–4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3–48.3); it increased to 81.7% (95% CI: 75.5–87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13–0.40; p < 0.001). Conclusion: The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients.
format Online
Article
Text
id pubmed-7465919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74659192020-09-04 Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer Fabbro, Michel Colombo, Pierre-Emmanuel Leaha, Cristina Marinella Rouanet, Philippe Carrère, Sébastien Quenet, François Gutowski, Marian Mourregot, Anne D’Hondt, Véronique Coupier, Isabelle Vendrell, Julie Vilquin, Paul Pujol, Pascal Solassol, Jérôme Mollevi, Caroline Cancers (Basel) Article Objective: High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ≥five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis. Methods: Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS. Results: 404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20–89), WHO performance status 0–1 in 86.9% and 2 in 13.1%, and Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1–14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6–4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3–48.3); it increased to 81.7% (95% CI: 75.5–87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13–0.40; p < 0.001). Conclusion: The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients. MDPI 2020-08-05 /pmc/articles/PMC7465919/ /pubmed/32764409 http://dx.doi.org/10.3390/cancers12082184 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fabbro, Michel
Colombo, Pierre-Emmanuel
Leaha, Cristina Marinella
Rouanet, Philippe
Carrère, Sébastien
Quenet, François
Gutowski, Marian
Mourregot, Anne
D’Hondt, Véronique
Coupier, Isabelle
Vendrell, Julie
Vilquin, Paul
Pujol, Pascal
Solassol, Jérôme
Mollevi, Caroline
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title_full Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title_fullStr Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title_full_unstemmed Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title_short Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
title_sort conditional probability of survival and prognostic factors in long-term survivors of high-grade serous ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465919/
https://www.ncbi.nlm.nih.gov/pubmed/32764409
http://dx.doi.org/10.3390/cancers12082184
work_keys_str_mv AT fabbromichel conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT colombopierreemmanuel conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT leahacristinamarinella conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT rouanetphilippe conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT carreresebastien conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT quenetfrancois conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT gutowskimarian conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT mourregotanne conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT dhondtveronique conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT coupierisabelle conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT vendrelljulie conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT vilquinpaul conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT pujolpascal conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT solassoljerome conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer
AT mollevicaroline conditionalprobabilityofsurvivalandprognosticfactorsinlongtermsurvivorsofhighgradeserousovariancancer